ARK Invest Shifts Portfolio from Tech to Biotech in Strategic Rebalancing
Cathie Wood's ARK Invest executed a series of notable trades on February 18, 2026, signaling a strategic pivot toward biotech equities. The firm allocated $4.33 million to Recursion Pharmaceuticals, acquiring 1,251,270 shares of the AI-driven drug discovery company. This follows accumulating positions in CRISPR Therapeutics, with 37,075 shares purchased for $1.97 million, reinforcing ARK's conviction in gene-editing technologies.
Concurrently, ARK divested from tech exposures, liquidating $3.89 million worth of PagerDuty shares and reducing stakes in Teradyne, DraftKings, and Salesforce. The moves reflect a calculated rotation into healthcare innovation at the expense of software and consumer discretionary holdings.